• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Choosing the right double-barreled gun: ARI0003 takes aim at lymphoma by targeting both CD19 and BCMA.

作者信息

Rampotas Alexandros, Gannon Isaac, Roddie Claire

机构信息

University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK; University College London Hospital, 235 Euston Road, London NW1 2BU, UK.

University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK.

出版信息

Mol Ther. 2025 Jan 8;33(1):23-25. doi: 10.1016/j.ymthe.2024.12.034. Epub 2024 Dec 20.

DOI:10.1016/j.ymthe.2024.12.034
PMID:39708800
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11764553/
Abstract
摘要

相似文献

1
Choosing the right double-barreled gun: ARI0003 takes aim at lymphoma by targeting both CD19 and BCMA.选择合适的双管枪：ARI0003通过靶向CD19和BCMA来瞄准淋巴瘤。
Mol Ther. 2025 Jan 8;33(1):23-25. doi: 10.1016/j.ymthe.2024.12.034. Epub 2024 Dec 20.
2
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.ARI0003：用于治疗非霍奇金淋巴瘤的共转导CD19/BCMA双靶点嵌合抗原受体T细胞。
Mol Ther. 2025 Jan 8;33(1):317-335. doi: 10.1016/j.ymthe.2024.11.028. Epub 2024 Nov 19.
3
Validation of BCMA-CD19 Compound CAR-T Therapy in SLE Overlap Syndrome: Over 1.5-Year Follow-Up.BCMA-CD19复合嵌合抗原受体T细胞疗法在系统性红斑狼疮重叠综合征中的验证：超过1.5年的随访
Stem Cell Rev Rep. 2025 Jun 23. doi: 10.1007/s12015-025-10923-7.
4
Bicistronic CAR-T Cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited.针对BCMA和CD229的双顺反子嵌合抗原受体T细胞即使在BCMA表达受限的情况下也能有效控制骨髓瘤。
Cancer Immunol Res. 2025 Jun 27. doi: 10.1158/2326-6066.CIR-24-1313.
5
Impact of a clinician-directed educational program on communicating with patients regarding gun violence at two community urban healthcare centers.一项由临床医生主导的教育项目对两家城市社区医疗中心就枪支暴力问题与患者沟通的影响。
J Osteopath Med. 2025 Jan 29;125(7):359-368. doi: 10.1515/jom-2024-0245. eCollection 2025 Jul 1.
6
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.当前抗骨髓瘤嵌合抗原受体T细胞：新靶点与新方法
Balkan Med J. 2025 Jul 1;42(4):301-310. doi: 10.4274/balkanmedj.galenos.2025.2025-4-25.
7
Effectiveness of Massage Gun Versus Myofascial Release Technique for Releasing Latent Trigger Points of the Calf Muscle: A Protocol for Randomized Clinical Trial.按摩枪与肌筋膜松解技术对释放小腿肌肉潜在触发点的有效性：一项随机临床试验方案
Physiother Res Int. 2025 Apr;30(2):e70055. doi: 10.1002/pri.70055.
8
IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.分泌白细胞介素-18 的多抗原靶向嵌合抗原受体 T 细胞在免疫功能正常的小鼠模型中消除低抗原骨髓瘤。
Blood. 2024 Jul 11;144(2):171-186. doi: 10.1182/blood.2023022293.
9
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma.病例报告：靶向BCMA的嵌合抗原受体T细胞疗法诱导复发的髓外浆母细胞性多发性骨髓瘤实现完全且持久的缓解。
Front Immunol. 2025 May 26;16:1567403. doi: 10.3389/fimmu.2025.1567403. eCollection 2025.
10
Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.骨髓瘤细胞内在的膜联蛋白A1升高和T细胞功能障碍导致CAR-T治疗后BCMA阴性复发。
Mol Ther. 2025 Jul 2;33(7):3375-3391. doi: 10.1016/j.ymthe.2025.03.001. Epub 2025 Mar 8.

本文引用的文献

1
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.用于治疗B细胞急性淋巴细胞白血病和B细胞非霍奇金淋巴瘤的双靶点嵌合抗原受体T细胞
Blood Adv. 2025 Feb 25;9(4):704-721. doi: 10.1182/bloodadvances.2024013586.
2
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.ARI0003：用于治疗非霍奇金淋巴瘤的共转导CD19/BCMA双靶点嵌合抗原受体T细胞。
Mol Ther. 2025 Jan 8;33(1):317-335. doi: 10.1016/j.ymthe.2024.11.028. Epub 2024 Nov 19.
3
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.双靶点 CAR-T 细胞（同时针对 CD19 和 CD22）治疗复发/难治性大 B 细胞淋巴瘤患者的效果。
Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598.
4
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.嵌合抗原受体 T 细胞治疗儿童及青年 B 细胞急性淋巴细胞白血病：1 期临床研究结果及新型双顺反子嵌合抗原受体的研发
Blood. 2022 Aug 4;140(5):451-463. doi: 10.1182/blood.2022015795.
5
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.嵌合抗原受体 T 细胞双重靶向 CD19 和 CD22 治疗儿童和青年复发/难治性 B 细胞急性淋巴细胞白血病患者：一项 1 期试验。
Nat Med. 2021 Oct;27(10):1797-1805. doi: 10.1038/s41591-021-01497-1. Epub 2021 Oct 12.
6
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.靶向CD19和CD22的双价嵌合抗原受体的临床前开发
Mol Ther Oncolytics. 2018 Nov 6;11:127-137. doi: 10.1016/j.omto.2018.10.006. eCollection 2018 Dec 21.
7
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.